These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 32558706

  • 1. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
    Schmidkonz C, Götz TI, Atzinger A, Ritt P, Prante O, Kuwert T, Bäuerle T, Goebell P, Cordes M.
    Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.
    Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, Prante O, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [Abstract] [Full Text] [Related]

  • 3. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 4. Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer.
    Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Clin Nucl Med; 2018 Aug; 43(8):e250-e258. PubMed ID: 29916921
    [Abstract] [Full Text] [Related]

  • 5. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [Abstract] [Full Text] [Related]

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Oct; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 8. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
    Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
    [Abstract] [Full Text] [Related]

  • 9. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
    Schmidkonz C, Atzinger A, Goetz TI, Beck M, Ritt P, Prante O, Kuwert T, Bäuerle T, Cordes M.
    Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
    [Abstract] [Full Text] [Related]

  • 10. The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.
    Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.
    Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
    [Abstract] [Full Text] [Related]

  • 11. First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer.
    Reinfelder J, Kuwert T, Beck M, Sanders JC, Ritt P, Schmidkonz C, Hennig P, Prante O, Uder M, Wullich B, Goebell P.
    Clin Nucl Med; 2017 Jan; 42(1):26-33. PubMed ID: 27775936
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.
    Li B, Duan L, Shi J, Han Y, Wei W, Cheng X, Cao Y, Kader A, Ding D, Wu X, Gao Y.
    Front Oncol; 2022 Jan; 12():1072437. PubMed ID: 36568205
    [Abstract] [Full Text] [Related]

  • 13. Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
    Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T.
    J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer.
    Brito AET, Mourato FA, de Oliveira RPM, Leal ALG, Filho PJA, de Filho JLL.
    Ann Nucl Med; 2019 May; 33(5):344-350. PubMed ID: 30746599
    [Abstract] [Full Text] [Related]

  • 15. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer.
    Santos A, Mattiolli A, Carvalheira JB, Ferreira U, Camacho M, Silva C, Costa F, Matheus W, Lima M, Etchebehere E.
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):493-500. PubMed ID: 32789680
    [Abstract] [Full Text] [Related]

  • 16. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
    Su HC, Zhu Y, Ling GW, Hu SL, Xu XP, Dai B, Ye DW.
    Asian J Androl; 2017 Dec; 19(3):267-271. PubMed ID: 27976632
    [Abstract] [Full Text] [Related]

  • 18. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.